• Aliases: Fosbretabulin tromethamine; NSC-348103; NSC-600168; SureCN19956; AC1L7IJ7
    • Binds to the β-subunit of tubulin at the colchicine site, thereby inhibiting the tubulin polymerization, resulting in the prevention of cancer cells from producing microtubules
    • Phase 1b/2 studies are under way for ovarian cancer, SCLC, esophageal cancer, and melanoma.
    • Recommended phase 2 dose: 45 mg/m2 IV over 10 minutes every week for 3 weeks, 1 week off in anaplastic thyroid cancer.
    • Half-life: â™1.9 hours
    • Common side effects: Pain, lymphopenia, fatigue, hypertension/hypotension, diarrhea, nausea/vomiting, visual disturbance, tachycardia
    (Mooney et al., 2009)
    Other topics in Targeted and Immunotherapy Agents